Morning Alert: Altria Group Inc. (NYSE:MO), Pandora Media Inc (NYSE:P), MakeMyTrip Limited (NASDAQ:MMYT), Astoria Financial Corporation (NYSE:AF), Merck & Co. Inc. (NYSE:MRK)

Altria Group Inc. (NYSE:MO) belongs to Consumer Goods sector. Its net profit margin is 19.80% and weekly performance is -0.64%. On last trading day company shares ended up $51.35. Altria Group Inc. (NYSE:MO) distance from 50-day simple moving average (SMA50) is 2.79%. Altria Group Inc (NYSE:MO)’s stock was boosted to “Outperform” by stock research analysts at CLSA. MO’s “Underperform” rating is no longer valid.

On 14 July, Pandora Media Inc (NYSE:P) shares fell -0.20% and was closed at $15.25. P EPS growth in last 5 year was 0.00%. Pandora Media Inc (NYSE:P) year to date (YTD) performance is -14.47%. Pandora Media Inc (NYSE:P) has closed a deal to acquire music analytics provider Next Big Sound for an undisclosed sum. The deal puts the finishing touches on a plan to give the industry more data about artists and their fans.

On 14 July, MakeMyTrip Limited (NASDAQ:MMYT) shares increased 6.10% and was closed at $19.65. MMYT EPS growth in last 5 year was -4.70%. MakeMyTrip Limited (NASDAQ:MMYT) year to date (YTD) performance is -24.39%. MakeMyTrip Limited (NASDAQ:MMYT) is expected to post quarterly earnings on 29 July 2015.

Astoria Financial Corporation (NYSE:AF) ended the last trading day at $13.97. Company weekly volatility is calculated as 1.50% and price to cash ratio as 4.56. Astoria Financial Corporation (NYSE:AF) showed a weekly performance of 3.18%. Astoria Financial Corporation (NYSE:AF) announced that it expects to report second quarter 2015 earnings on Wednesday, July 22, 2015 at approximately 4:45 p.m. Eastern Time (ET).

Merck & Co. Inc. (NYSE:MRK) ended the last trading day at $58.19. Company weekly volatility is calculated as 1.25% and price to cash ratio as 10.54. Merck & Co. Inc. (NYSE:MRK) showed a weekly performance of 0.34%. Merck & Co. Inc. (NYSE:MRK) and Allergan plc (AGN) released that they have signed into an contract under which Allergan will purchase the exclusive worldwide rights to Merck’s investigational small molecule oral calcitonin gene-related peptide receptor antagonists, which are being developed for the treatment and prevention of migraine.

Leave a Reply

Your email address will not be published. Required fields are marked *